Endocannabinoid-System-Ecs Medical Cannabis Studies

• View All (505)

Cannabis, a complex plant: different compounds and different effects on individuals (2012)

In the present article a vision of the biochemical bases of cannabis research is shown by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and the different effects on individuals. View study
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System (2014)

In this investigation it was discovered that CB2 receptors can form heteromers with CB1 receptors in transfected neuronal cells and in pineal gland of rat brain, nucleus accumbens and pale globe. In general, the data obtained in this research illuminates the mechanism by which CB2 receptors can negatively modulate CB1 receptor function. View study
Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions (2014)

In this study, the bibliographical review available related to the clinical deficiency of endocannabinoids (CECD) was carried out. Research results have confirmed that the underlying endocannabinoid deficiencies play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. View study
Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions (2004)

The present study demonstrates that migraine, fibromyalgia, and other related conditions have common clinical, biochemical, and pathophysiologic patterns that could be treated with cannabinoid medications. View study
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes (2016)

In this research a reconsideration of the clinical endocannabinoid deficiency is made. Current research supports the theory of migraine, fibromyalgia, irritable bowel and other treatment-resistant syndromes View study
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown (2010)

This review focuses on the binding of endocannabinoids to cannabinoid receptors. It is based on experimental and computational studies that have been used to demonstrate the nature of the interaction of endocannabinoids with cannabinoid receptors. View study
Endocannabinoid Signaling Regulates Sleep Stability (2016)

In this study we will show the results of a series of experiments in mice that measure sleep with polysomnography after several systemic pharmacological manipulations of the endocannabinoid system. The results support the hypothesis that endocannabinoid signaling through type 1 cannabinoids (CB1) is necessary for the stability of non-rapid eye movements (NREM), but is not necessary for sleep homeostasis. View study
Endocannabinoid signalling and the deteriorating brain (2015)

This research focused on endocannabinoid signaling and brain deterioration. After the approval of the first cannabinoid-based drug for the symptomatic treatment of multiple sclerosis, we investigated how endocannabinoid signaling (eCB) controls and is affected by normal aging and neuroinflammatory and neurodegenerative disorders. View study
Endocannabinoid System in First Trimester Placenta- Low FAAH and High CB1 Expression Characterize Spontaneous Miscarriage (2009)

Endocannabinoid levels are critical to regulate embryonic development and the window of implantation. Placental tissue represents a target for endocannabinoids, whose activity can regulate the outcome of pregnancy. View study
Endocannabinoids and energy homeostasis: An update (2014)

This article studies how the endocannabinoid tone, in addition to reinforcing the reward circuits and the modulation of food intake and health, controls the metabolism of lipids and glucose in several peripheral organs, particularly the liver and adipose tissue. This study gives a new focus on endocannabinoid control of the neurochemical causes and consequences of the imbalance of energy homeostasis, an approach that could lead to new potential treatments for obesity and related morbidities. View study
Endocannabinoids and the haematological system (2007)

This research aims to review the interactions between cannabinoids and the hematological system. Endocannabinoids can regulate platelet function and possibly lead to thrombogenesis, and influence hematopoiesis. View study
Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol (2007)

These findings suggest that the local activity of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL) and cyclooxygenase (COX), which is present to a large extent in the endothelium, limits the vasodilator action of endocannabinoids in the arteries small mesenteric rat. Despite the differential roles that these enzymes make in relaxation to anandamide versus 2-AG, the results indicate that the inhibitors of these enzymes increase the vascular impact of the endocannabinoids. View study